Tango Therapeutics Statistics
Share Statistics
Tango Therapeutics has 108.39M
shares outstanding. The number of shares has increased by 1.18%
in one year.
| Shares Outstanding | 108.39M |
| Shares Change (YoY) | 1.18% |
| Shares Change (QoQ) | 0.64% |
| Owned by Institutions (%) | 98.1% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 1,565 |
| FTD / Avg. Volume | 0.11% |
Short Selling Information
The latest short interest is 12.55M, so 11.61% of the outstanding
shares have been sold short.
| Short Interest | 12.55M |
| Short % of Shares Out | 11.61% |
| Short % of Float | 14.02% |
| Short Ratio (days to cover) | 21.63 |
Valuation Ratios
The PE ratio is -2.59 and the forward
PE ratio is -1.42.
Tango Therapeutics's PEG ratio is
-0.25.
| PE Ratio | -2.59 |
| Forward PE | -1.42 |
| PS Ratio | 8.02 |
| Forward PS | 1.2 |
| PB Ratio | 1.69 |
| P/FCF Ratio | -2.55 |
| PEG Ratio | -0.25 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Tango Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.98,
with a Debt / Equity ratio of 0.18.
| Current Ratio | 6.98 |
| Quick Ratio | 6.98 |
| Debt / Equity | 0.18 |
| Debt / EBITDA | -0.25 |
| Debt / FCF | -0.28 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $271,412.9 |
| Profits Per Employee | $-840,658.06 |
| Employee Count | 155 |
| Asset Turnover | 0.13 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 208K |
| Effective Tax Rate | -0.16% |
Stock Price Statistics
The stock price has increased by -73.48% in the
last 52 weeks. The beta is 1.03, so Tango Therapeutics's
price volatility has been higher than the market average.
| Beta | 1.03 |
| 52-Week Price Change | -73.48% |
| 50-Day Moving Average | 1.5 |
| 200-Day Moving Average | 4.36 |
| Relative Strength Index (RSI) | 58.62 |
| Average Volume (20 Days) | 1,396,591 |
Income Statement
In the last 12 months, Tango Therapeutics had revenue of 42.07M
and earned -130.3M
in profits. Earnings per share was -1.19.
| Revenue | 42.07M |
| Gross Profit | 39.57M |
| Operating Income | -145.59M |
| Net Income | -130.3M |
| EBITDA | -145.59M |
| EBIT | -145.59M |
| Earnings Per Share (EPS) | -1.19 |
Full Income StatementBalance Sheet
The company has 69.53M in cash and 36.49M in
debt, giving a net cash position of 33.04M.
| Cash & Cash Equivalents | 69.53M |
| Total Debt | 36.49M |
| Net Cash | 33.04M |
| Retained Earnings | -501.56M |
| Total Assets | 274.31M |
| Working Capital | 189.01M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -131.5M
and capital expenditures -754K, giving a free cash flow of -132.25M.
| Operating Cash Flow | -131.5M |
| Capital Expenditures | -754K |
| Free Cash Flow | -132.25M |
| FCF Per Share | -1.21 |
Full Cash Flow StatementMargins
Gross margin is 94.06%, with operating and profit margins of -346.09% and -309.73%.
| Gross Margin | 94.06% |
| Operating Margin | -346.09% |
| Pretax Margin | -309.24% |
| Profit Margin | -309.73% |
| EBITDA Margin | -346.09% |
| EBIT Margin | -346.09% |
| FCF Margin | -314.38% |
